SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Conditions: Squamous Cell Carcinoma of the Head and Neck; Melanoma; Non Small Cell Lung Cancer; Urothelial Carcinoma; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Squamous Cell Carcinoma of the Anus; Squamous Cell Carcinoma of the Cervix; Squamous Cell Carcinoma of the Skin; Renal Cell Carcinoma; Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; Mismatch Repair Deficient or MSI-High Solid Tumors
Intervention: Drug: SL-279252
Sponsor: Shattuck Labs, Inc.
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.